Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...

Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the ...

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...

William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Jones Financial Companies Lllp boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...